Although previous studies have shown the superiority of GLP‐1 RAs compared with placebo in terms of major adverse cardiovascular events (MACEs), mortality, and stroke [6, 7], there is a paucity of data on cardiovascular efficacy of GLP‐1 RAs in patients without diabetes. The gene discussed is GLP1R; the disease is Stroke.